Waters Corporation (WAT)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$374.93-1.05%
Close 2026-07-07 · 1-day change
Reading WAT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WAT free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading WAT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WAT free→QuarterlyIQ Insights · WAT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $374.93. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $375 WAT trades at 28× p/e, below its 35× p/e peer median, but our blended $333 fair value sits below the price. It's a high-confidence read. Analysts target $350–$435. Note: our $333 fair value sits below the entire analyst range ($350–$435). Not investment advice.
$350.00 – $435.00 (median $400.00) · 7 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 225224% over what the business is worth with no growth; closing that gap needs roughly 22.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.01/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2025-Q4, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $400.00 | — | — | Analyst | high |
| Mgmt guidance | 12M | $512.18 | 35.3 | 14.50 | Mgmt | high |
| Peer P/E | 12M | $479.68 | 35.3 | 13.58 | TTM | high |
| PEG | 12M | $724.61 | 53.4 | 13.58 | TTM | high |
| residual income | 12M | $52.33 | — | — | TTM | high |
| Own P/E history | 12M | $378.51 | 27.9 | 13.58 | TTM | high |
| triangulated | 12M | $486.69 | 35.3 | 13.78 | Triangulated | high |
| Mgmt guidance | 3Y | $756.36 | 35.3 | 21.41 | Mgmt(prov.) | medium |
| Peer P/E | 3Y | $708.37 | 35.3 | 20.05 | Analyst | medium |
| PEG | 3Y | $1070.08 | 53.4 | 20.05 | Analyst | medium |
| Own P/E history | 3Y | $558.97 | 27.9 | 20.05 | Analyst | medium |
| Mgmt guidance | 5Y | $980.85 | 35.3 | 27.77 | Mgmt(prov.) | high |
| Peer P/E | 5Y | $918.61 | 35.3 | 26.01 | Analyst | high |
| PEG | 5Y | $1387.67 | 53.4 | 26.01 | Analyst | high |
| Own P/E history | 5Y | $724.86 | 27.9 | 26.01 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.